Supernus Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Supernus Pharmaceuticals's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 9% to $607,521,000. Profit margin reached 0%. Total operating expenses were $529,011,000.
Profit Margin
| 2014 | 122.04M | 19.87M | 16.28% |
|---|---|---|---|
| 2015 | 144.42M | 14.01M | 9.7% |
| 2016 | 215.00M | 91.22M | 42.43% |
| 2017 | 302.23M | 57.28M | 18.95% |
| 2018 | 408.89M | 110.99M | 27.14% |
| 2019 | 392.75M | 113.05M | 28.79% |
| 2020 | 520.39M | 126.95M | 24.39% |
| 2021 | 579.77M | 53.42M | 9.21% |
| 2022 | 667.23M | 60.71M | 9.1% |
| 2023 | 607.52M | 1.31M | 0.22% |
SUPN Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 607.52M | 667.23M | 579.77M | 520.39M | 392.75M | 408.89M | 302.23M | 215.00M | 144.42M | 122.04M |
Cost of revenue | 83.77M | 87.22M | 75.06M | 52.45M | 16.66M | 15.35M | 15.21M | 11.98M | 8.42M | 5.75M |
Gross profit | 523.74M | 580.01M | 504.71M | 467.93M | 376.09M | 393.54M | 287.02M | 203.01M | 136.00M | 116.28M |
Operating exp. | ||||||||||
Research and development | 91.59M | 74.55M | 90.46M | 75.96M | 69.09M | 89.20M | 49.57M | 42.79M | 29.13M | 19.58M |
Selling and marketing | 99.7M | 267.78M | 199.70M | 134.75M | 40.8M | 43.3M | 33.8M | 21.9M | 19.3M | 14.8M |
Total operating expenses | 529.01M | 534.40M | 425.21M | 292.34M | 227.52M | 249.09M | 187.48M | 148.80M | 118.33M | 92.05M |
Operating income | -5.26M | 67.30M | 86.02M | 173.69M | 148.57M | 144.44M | 99.54M | 54.21M | 17.66M | 24.23M |
Other income (expenses), net | 8.03M | -6.56M | -12.85M | -5.05M | -1.08M | -4.26M | 1.07M | -238K | -6.23M | -4.35M |
Income before tax | 2.76M | 60.74M | 73.17M | 168.64M | 147.48M | 140.17M | 100.61M | 50.36M | 14.97M | 19.87M |
Income tax expense | 1.45M | 32K | 19.75M | 41.69M | 34.43M | 29.18M | 43.33M | -40.85M | 956K | 4.03M |
Net income | 1.31M | 60.71M | 53.42M | 126.95M | 113.05M | 110.99M | 57.28M | 91.22M | 14.01M | 19.87M |
Earnings per share | ||||||||||
Basic EPS | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 | 0.29 | 0.47 |
Diluted EPS | 0.02 | 1.04 | 0.98 | 2.36 | 2.1 | 2.05 | 1.08 | 1.76 | 0.28 | 0.32 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |